CoChat

Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver

Open access
Schmitt, C., Lenglet, H., Yu, A., Delaby, C., Benecke, A., Lefebvre, T., Letteron, P., Paradis, V., Wahlin, S., Sandberg, S., Harper, P., Sardh, E., Sandvik, A. K., Hov, J. R., Aarsand, A. K., Chiche, L., Bazille, C., Scoazec, J.‐Y., To-Figueras, J., Carrascal, M., Abian, J., Mirmiran, A., Karim, Z., Deybach, J.‐C., Puy, H., Peoc'h, K., Manceau, H., Gouya, L. · 2018 · Journal of Internal Medicine
Cited by 121

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background: Acute intermittent porphyria (AIP) is an inherited disorder of haem metabolism characterized by life‐threatening acute neurovisceral attacks due to the induction of hepatic δ‐aminolevulinic acid synthase 1 (ALAS 1) associated with hydroxymethylbilane synthase (HMBS) deficiency. So far, the treatment of choice is hemin which represses ALAS 1. The main issue in the medical care of AIP patients is the occurrence of debilitating recurrent attacks. Objective: The aim of this study was to determine whether chronic hemin administration contributes to the recurrence of acute attacks. Methods: A follow‐up study was conducted between 1974 and 2015 and included 602 French AIP patients, of whom 46 had recurrent AIP. Moreover, we studied the hepatic transcriptome, serum proteome, liver macrophage polarization and oxidative and inflammatory profiles of Hmbs−/− mice chronically treated by hemin and extended the investigations to five explanted livers from recurrent AIP patients. Results: The introduction of hemin into the pharmacopeia has coincided with a 4.4‐fold increase in the prevalence of chronic patients. Moreover, we showed that both in animal model and in human liver, frequent hemin infusions generate a chronic inflammatory hepatic disease which induces HO 1 remotely to hemin treatment and maintains a high ALAS 1 level responsible for recurrence. Conclusion: Altogether, this study has important impacts on AIP care underlying that hemin needs to be restricted to severe neurovisceral crisis and suggests that alternative treatment targeting the liver such as ALAS 1 and HO 1 inhibitors, and anti‐inflammatory therapies should be considered in patients with recurrent AIP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/joim.12750

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 121

Metadata

Authors
Schmitt, C., Lenglet, H., Yu, A., Delaby, C., Benecke, A., Lefebvre, T., Letteron, P., Paradis, V., Wahlin, S., Sandberg, S., Harper, P., Sardh, E., Sandvik, A. K., Hov, J. R., Aarsand, A. K., Chiche, L., Bazille, C., Scoazec, J. ‐., To-Figueras, J., Carrascal, M., Abian, J., Mirmiran, A., Karim, Z., Deybach, J. ‐., Puy, H., Peoc'h, K., Manceau, H., & Gouya, L.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
2018-03-26
Volume
284
Issue
1
Pages
78-91
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
OpenAlex
W2790744750
Cited by
121
References
6
FWCI
4.71
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.